Why the study?
Does aliskiren improve blood pressure and myocardial function assessed by global longitudinal strain in patients with uncontrolled arterial hypertension and diastolic dysfunction?
Does aliskiren improve blood pressure and myocardial function assessed by global longitudinal strain in patients with uncontrolled arterial hypertension and diastolic dysfunction?
Adding aliskiren to combined antihypertensive therapy significantly improves blood pressure control and myocardial function as assessed by global longitudinal strain in patients with uncontrolled hypertension and diastolic dysfunction.
Aliskiren addition was associated with improved strain; hypothesis-generating and requires RCTs before changing practice in uncontrolled hypertension.
OBJECTIVE: To evaluate the effects of aliskiren on blood pressure and myocardial function assessed by global longitudinal strain in patients with uncontrolled arterial hypertension. PATIENTS AND METHODS: Forty-five patients were included in the study (29 males, 16 females, mean age 58.7 +/- 12.4 years) with BP > 140/90 mmHg despite treatment with combined antihypertensive therapy and echocardiographic data for diastolic dysfunction: E/E'ratio < or = 8, E/A ratio < 0.8, deceleration time (DT) > 200 msec. Aliskiren (2 x 150 mg per day) was added to the previous therapy. The follow-up period was 1 year, including monthly clinical visits. Echocardiographic assessment of the left ventricular function by longitudinal strain and Doppler analysis of the trans-mitral blood flow was performed at months 1, 6, 12. RESULTS: The baseline systolic and diastolic blood pressures scores were 153.4 +/- 14.4/99.2 +/- 6.7 mmHg and 157.6 +/- 12.5/97.3 +/- 8.2 mmHg for males and females, respectively. The systolic and diastolic values at 1 month were 131.7 +/- 7.4/83.6 +/- 5.2 mmHg for males and 132.4 +/- 5.3/81.8 +/- 6.9 mmHg for females (p < 0.05 vs. baseline). The baseline E/E' was 6.5 +/- 0.9, E/A - 0.6 +/- 001, DT - 258 +/- 32.7 msec. These indicators at month 12 were as follows: E/E' - 7.0 +/- 0.64, E/A - 0.7 +/- 0.05, DT - 239 +/- 16.5 msec, p = NS. Baseline global longitudinal strain in males was -10.4 +/- 0.7% and -11.0 +/- 0.9% in females and at month 12 - 16.3 +/- 0.9% and -17.5 +/- 0.7% for males and females, respectively, p < 0.05. For the period of follow-up no adverse effects due to aliskiren treatment were registered. CONCLUSIONS: Adding aliskiren to combined antihypertensive therapy leads to significant improvement of hypertension control and myocardial function assessed by global longitudinal strain.
No takes yet. Share an insight, caveat, or question.
Manov et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: